Clinical trials & pipeline
We are advancing a diverse and promising portfolio of clinically differentiated compounds through internal development and strategic external partnerships.
+ Cybrexa Therapeutics and Exelixis have an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12
* Sairopa B.V. (Sairopa) and Exelixis have an exclusive clinical development and option agreement providing Exelixis the right to acquire ADU-1805
Disclaimer: The compounds presented are investigational or are being investigated for uses that have not been approved by the U.S. Food and Drug Administration. The safety and efficacy of these investigational compounds and/or investigational uses have not been established. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.
- Discovery/Preclinical Disc/Pre
- IND IND
- Phase 1A Phase 1A
- Phase 1B Phase 1B
- Phase 2/3 Phase 2/3
CONTACT-02 (mCRPC): Complete enrollment and report pivotal top-line PFS data in second half 2023
CONTACT-02 (mCRPC): Complete enrollment and report pivotal top-line PFS data in second half 2023
COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC): Report OS analysis by year-end 2023
COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC): Report OS analysis by year-end 2023
Multi-TKI targeting MET/VEGFR/AXL/RET
Multi-TKI targeting MET/VEGFR/AXL/RET
CONTACT-02 (mCRPC): Complete enrollment and report pivotal top-line PFS data in second half 2023
CONTACT-02 (mCRPC): Complete enrollment and report pivotal top-line PFS data in second half 2023
COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC): Report OS analysis by year-end 2023
COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC): Report OS analysis by year-end 2023
STELLAR-304 (nccRCC)
STELLAR-304 (nccRCC)
STELLAR-303 (CRC)
STELLAR-303 (CRC)
STELLAR-002 (Solid tumors)
STELLAR-002 (Solid tumors)
STELLAR-001 (Solid tumors)
STELLAR-001 (Solid tumors)
XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER
XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER
STELLAR-304 (nccRCC)
STELLAR-304 (nccRCC)
STELLAR-303 (CRC)
STELLAR-303 (CRC)
STELLAR-002 (Solid tumors)
STELLAR-002 (Solid tumors)
STELLAR-001 (Solid tumors)
STELLAR-001 (Solid tumors)
QUARTZ-101 (Solid tumors)
QUARTZ-101 (Solid tumors)
Oral CDK7 inhibitor
Oral CDK7 inhibitor
QUARTZ-101 (Solid tumors)
QUARTZ-101 (Solid tumors)
Next-generation 5T4-targeting ADC
Next-generation 5T4-targeting ADC
Bispecific antibody targeting PD-L1 + CD47
Bispecific antibody targeting PD-L1 + CD47
Bispecific antibody targeting PD-L1 + NKG2A
Bispecific antibody targeting PD-L1 + NKG2A
Next-generation TF-topoisomerase ADC
Next-generation TF-topoisomerase ADC
Non-disclosed
Non-disclosed
Non-disclosed
Non-disclosed
ADAR1
ADAR1
PKMYT1 inhibitors
PKMYT1 inhibitors
AMHR2, ROR1/2, TF, DLL3
AMHR2, ROR1/2, TF, DLL3
+Cybrexa Therapeutics and Exelixis have an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12
* Sairopa B.V. (Sairopa) and Exelixis have an exclusive clinical development and option agreement providing Exelixis the right to acquire ADU-1805
- ADAR1 = adenosine deaminase 1
- ADC = antibody-drug conjugate
- AMHR2 = anti-mullerian hormone receptor 2
- CDK7 = cyclin-dependent kinase 7
- CDK12 = cyclin-dependent kinase 12
- CRC = colorectal cancer
- DLL3 = delta-like ligand 3
- IND = investigational new drug application
- mAb = monoclonal antibody
- MALT1 = mucosa associated lymphoid tissue lymphoma translocation gene 1
- mCRPC = metastatic castration-resistant prostate cancer
- nccRCC = non-clear cell renal cell carcinoma
- NKG2A = natural killer cell receptor group 2A
- OS = overall survival
- PD-L1 = programmed death-ligand 1
- PFS = progression-free survival
- PKMYT1 = protein kinase, membrane associated tyrosine/threonine 1
- RCC = renal cell carcinoma
- ROR1/2 = receptor tyrosine kinase like orphan receptor 1/2
- SIRPα = signal regulatory protein alpha
- TF = tissue factor
- TKI = tyrosine kinase inhibitor
Disclaimer: The compounds presented are investigational or are being investigated for uses that have not been approved by the U.S. Food and Drug Administration. The safety and efficacy of these investigational compounds and/or investigational uses have not been established. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.